scholarly journals Cruciferous Vegetable Intervention to Prevent Cancer Recurrence in Non-Muscle Invasive Bladder Cancer Survivors: Development using a Systematic Process (Preprint)

JMIR Cancer ◽  
10.2196/32291 ◽  
2021 ◽  
Author(s):  
Karen Yeary ◽  
Nikia Clark ◽  
Frances Saad-Harfouche ◽  
Deborah Erwin ◽  
Margaret Kuliszewski ◽  
...  
2021 ◽  
Author(s):  
Karen Yeary ◽  
Nikia Clark ◽  
Frances Saad-Harfouche ◽  
Deborah Erwin ◽  
Margaret Kuliszewski ◽  
...  

BACKGROUND Bladder cancer is one of the top 10 most common cancers in the US. Most bladder cancer (70-80%) is diagnosed at early stages as non-muscle invasive bladder cancer (NMIBC), which can be removed surgically. However, 50-80% of NMIBC recurs within 5 years, and 15-30% progresses with poor survival. Current treatment is limited and expensive. A wealth of preclinical and epidemiologic evidence suggests that dietary isothiocyanates (ITCs) in cruciferous vegetables (Cruciferae) could be a novel, non-invasive, and cost-effective strategy to control NMIBC recurrence and progression. Yet a scalable dietary intervention that increases ITC exposure through Cruciferae intake in NMIBC survivors has not been developed. OBJECTIVE This paper will describe a systematic process through which a dietary intervention for bladder cancer survivors was developed that can serve as a model for others who aim to develop evidence-based behavioral interventions for cancer prevention. METHODS We used a systematic process to adapt evidence-based dietary interventions into a Cruciferae intervention for NMIBC survivors. We 1) identified relevant factors, evidence-based behavioral techniques, and behavioral theory constructs used to increase cruciferae intake in NMIBC survivors; 2) used the PEN-3 model to review the intervention’s components (e.g. saliency of behavioral messages); 3) administered the revised intervention to community partners for their feedback; and 4) refined the intervention based on Step 3. RESULTS We developed a multi-component intervention for NMIBC survivors consisting of a magazine, tracking book, a live phone-call script, and interactive voice messages (IVR). Entitled “POW-R Health: Power to Redefine Your Health”, the intervention incorporated findings from our adaptation process to ensure saliency to NMIBC survivors. CONCLUSIONS This is the first evidence-based, theoretically grounded dietary intervention developed to reduce bladder recurrence in NMIBC survivors using a systematic process for community adaptation. This study provides a model for others who aim to develop behavioral, community-relevant interventions for cancer prevention/control, with the overall goal of wide-scale implementation and dissemination.


2020 ◽  
pp. 1-5
Author(s):  
Łukasz Białek ◽  
Katarzyna Czerwińska ◽  
Łukasz Fus ◽  
Wojciech Krajewski ◽  
Anna Sadowska ◽  
...  

BACKGROUND: Mini Chromosome Maintenance 5 (MCM5) is considered as a urinary biomarker of bladder cancer. ADXBLADDER is a commercially available test to detect MCM5 antibodies. OBJECTIVE: External validation of ADXBLADDER test as a urinary biomarker of histopathologically confirmed non-muscle invasive bladder cancer (NMIBC) recurrence. METHODS: The study enrolled 119 consecutive patients with a history of NMIBC and 37 healthy volunteers matched as controls. Single, full-void urine samples were collected from patients before cystoscopy ± TUR. To measure MCM5 expression, Arquer Diagnostics ADXBLADDER test was used. The study protocol was registered within the clinical trials database (NCT03796299). RESULTS: Among patients with NMIBC history, recurrence was diagnosed in 83 patients (69.7%). ADXBLADDER demonstrated sensitivity of 73.5% (95% confidence interval (CI) 62.7%–82.6%), specificity of 33.3% (95% CI 18.6% to 51%), overall negative predictive value (NPV) of 35.3% (95% CI 23.3% to 49.5%) and overall positive predictive value of 71.8% (95% CI 66.1% to 76.8%) for detecting recurrence. In a control group, false positive ADXBLADDER results were noticed in 18 patients (48.6%). The sensitivity and NPV were the highest in invasive tumors (100% and 100%, respectively) and in high-grade recurrences (81.8% and 94.1%, respectively). CONCLUSIONS: ADXBLADDER has a moderate sensitivity and poor specificity in detecting NMIBC recurrence. However, it properly diagnoses patients with T1+ stage recurrence or high-grade tumors.


2020 ◽  
Vol 6 (1) ◽  
pp. 9-23
Author(s):  
Kyle B. Zuniga ◽  
Rebecca E. Graff ◽  
David B. Feiger ◽  
Maxwell V. Meng ◽  
Sima P. Porten ◽  
...  

Medicine ◽  
2015 ◽  
Vol 94 (22) ◽  
pp. e898 ◽  
Author(s):  
Chuanliang Xu ◽  
Shuxiong Zeng ◽  
Zhensheng Zhang ◽  
Ruixiang Song ◽  
Chong Ma ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document